Aflac (AFL) Earnings Date & Reports

Key Takeaways

• Adjusted diluted EPS (earnings per share) came in at $2.43, well above the $1.80 consensus estimate, helped by reserve remeasurement gains and a stronger U.S. segment.
• Adjusted earnings fell 8.5% to $1.2 billion, while GAAP (Generally Accepted Accounting Principles) net earnings tumbled 81.5% to $303 million, or $0.61 per diluted share, on a $1.1 billion portfolio-repositioning loss.
• Aflac U.S. pretax adjusted earnings rose 31.5% to $493 million, while Aflac Japan pretax adjusted earnings declined 15.2% in yen terms.
• Management raised its 2026 Aflac Japan pretax profit-margin outlook to 35%–38% and pointed to roughly $1 billion of potential capital release through reinsurance.
• The company returned $1.1 billion to shareholders and declared a fourth-quarter dividend of $0.61 per share.
• For more context, explore Aflac's Major News, Today's Price Move, Price Targets, and Forecast on Tickeron.
• Discover Trending AI Robots to see how AI-driven trading strategies are navigating current market conditions.

Earnings Context and Why It Matters

Aflac Incorporated is a leading supplemental health and life insurer with two dominant franchises: Aflac U.S., a core provider of accident, cancer, and voluntary benefits, and Aflac Japan, which holds a majority share of Japan's cancer-insurance market. Its third-quarter 2026 report carries extra weight because the results separate a resilient underlying operating performance from a sizable, one-time investment repositioning. For investors, the quarter tests whether Aflac can sustain earnings power in its U.S. business while managing yen-related pressure, cybersecurity costs, and shifting actuarial assumptions in Japan. With the stock near multi-year highs heading into the release, the market was watching closely for signs on margins, capital deployment, and guidance.

Reported Results

For the quarter ended September 30, 2026, Aflac posted adjusted diluted EPS of $2.43, surpassing the consensus estimate of $1.80 by roughly $0.62, or about 35%. Adjusted revenues of approximately $4.3 billion came in modestly above the consensus of about $4.2 billion, though down about 9% from $4.74 billion a year earlier. Adjusted earnings declined 8.5% to $1.2 billion, with the quarter benefiting from about $453 million in reserve remeasurement gains.

On a GAAP basis, results were sharply weaker. Net earnings fell 81.5% to $303 million, or $0.61 per diluted share, as the company recognized a $1.1 billion investment loss tied largely to deliberate portfolio repositioning, including an additional $2.3 billion switch trade involving Japanese government bonds. A $51 million tax valuation allowance also weighed on the headline figure.

Segment results were mixed. Aflac U.S. delivered pretax adjusted earnings of $493 million, up 31.5%, with net earned premiums up 3.3% to about $1.5 billion and the pretax margin widening to 27.7%. Aflac Japan's pretax adjusted earnings fell 15.2% to ¥152.3 billion, with its margin narrowing to 44.4% from 52.2%, partly reflecting higher benefits and cybersecurity-related expenses.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF (exchange-traded fund) discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to surface trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors following earnings-driven moves like Aflac's, it can serve as a practical way to identify related patterns and ideas across the insurance sector and beyond.

Market Reaction and Investor Sentiment

Heading into the release, sentiment on Aflac was cautious but constructive. Wall Street had pegged a notably low consensus EPS estimate, reflecting expectations for investment losses and cost pressures in Japan. Aflac shares had added roughly 12.5% since the start of the year, outpacing the broader market, and the stock was trading near its 52-week high despite a mixed analyst stance. The large adjusted EPS beat was driven in part by reserve remeasurement gains and a much stronger U.S. margin, which investors are likely to view favorably even as the GAAP investment loss draws attention. The key question for the market is whether the improved Japan margin outlook and reinsurance-driven capital release can offset near-term earnings pressure from the investment repositioning and cybersecurity costs.

Forward Outlook and Key Factors to Monitor

Looking ahead, investors will focus on whether Aflac's improved guidance translates into sustained profitability. Management raised its 2026 Aflac Japan pretax margin outlook to 35%–38%, signaling confidence despite the recent cyber incident and rising benefit costs. In the U.S., the pretax margin is now expected to finish above the 17%–20% range, reflecting strong recent performance.

Capital deployment remains a central theme. Aflac ceded roughly ¥500 billion of cancer-policy reserves to Aflac Re Bermuda, a move management estimates could release about $1 billion of capital over time while reducing risk and improving balance-sheet efficiency. How and when that capital is redeployed will be closely watched.

Other factors worth monitoring include the trajectory of the U.S. benefit ratio, the yen's exchange-rate impact on Japan earnings, and whether the portfolio repositioning delivers its projected lift to annual net investment income. Aflac reported an estimated regulatory solvency margin ratio (ESR) of 225% and combined risk-based capital (RBC) above 575%, indicating a strong capital buffer. The company also returned $1.1 billion to shareholders through buybacks and dividends, underscoring its commitment to capital return even amid a challenging quarter.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations